Browsing by Author "Atalay, F."

Now showing 1 - 3 of 3

Cochlear Synaptopathy Evaluation With Electrocochleography in Patients With Hearing Difficulty in Noise Despite Normal Hearing Levels
(2024) Yaşar, M.; Öner, F.; Atalay, F.; Anbar, S.S.
Objective: This study examined patients with normal hearing thresholds who had trouble understanding speech in noise. We used electrocochleography (ECochG) to detect and compare SP/AP amplitude area ratios, a potential indicator of cochlear synaptopathy, and investigate speech perception disorder in noise. Methods: The study included 68 people aged between 18 and 65 years, 35 patients and 33 healthy volunteers, who applied to the otorhinolaryngology clinic between November 2023 and March 2024 with a 2-month history of difficulty understanding speech in noisy environments. Everyone was given a tiptrode electrode ECochG test, and the results were compared between groups. An ECochG test was recorded with tiptrode electrodes and was performed on all participants, and the results were compared between groups. Results: In the ECochG test, the summation potential/action potential (SP/AP) amplitude and area ratios of patients who had difficulty understanding speech in a noisy environment were statistically higher than those of the control group. Conclusion: ECochG testing may provide additional evidence to evaluate auditory nerve pathways.
Comparison of clinic and demographic characteristics in vestibular migraine and migraine only patients
(2024.01.01) Kocaturk, I.; Atalay, F.; Anbar, S.S.
Background & Objective: The relationship between vertigo and migraine has been known for a long time. Many migraine patients are accompanied by vertigo. The term vestibular migraine (VM) is a clinical entity defined recently. Treatments for migraine only (MO) and VM patients differ partially. Therefore, it is essential to distinguish between these two clinical conditions. This study aims to reveal the clinical and demographic differences between MO and VM and determine the factors that will help diagnose and manage VM. Method: A total of 80 patients, 40 diagnosed with MO according to ICHD-3 and 40 diagnosed with VM, who applied to the Neurology clinic of a tertiary hospital between January and July 2023, were included in this prospective study. The patients' ages, genders, education levels, medical and family history, migraine duration, migraine onset age, migraine attack frequency, and medication use were recorded. All patients completed a battery of questionnaires, including the World Health Organization Quality of Life-Bref (WHOQOL-BREF), Dizziness Handicap Inventory (DHI), Activities-Specific Balance Confidence Scale (ABCS), and Beck Depression Inventory (BDI). Results: Patients with VM experienced significantly more sleep disturbances, depressive symptoms, movement disorders, imbalance, menstruation-related headaches, and aura compared to those with migraine MO. In contrast, MO patients reported more throbbing headaches and a better response to analgesics. Conclusion: MO and VM patients have distinct clinical characteristics. Recognizing these basic differences has important clinical benefits, allowing for precise diagnosis and treatment of VM.
Otoprotective Mechanisms of Carvone As An Antioxidant Agent Against Ototoxic Damage Caused By Paclitaxel
(2023.01.01) Dincer, B.; Atalay, F.; Tatar, A.
Objective: Ototoxicity is cellular damage caused by the use of solid treatments as chemotherapeutics in critical illnesses like cancer. The generation of free radicals is linked to fluctuating hearing loss caused by chemotherapeutics. Antioxidants can help to prevent ototoxicity-related oxidative damage. Carvone (CVN) is a monoterpene with excellent antioxidant properties that protect against oxidative damage. This study investigates the biochemical and functional aspects of CVN's putative otoprotective mechanisms against paclitaxel (PCX)-induced ototoxicity. Methods: 24 Wistar albino rats were assigned into four different groups: Control, CVN, PCX, and PCX+CVN. Once a week, the control group received saline. The PCX group received 5 mg/kg PCX intraperitoneally once a week (4 times). Once a week, the CVN group received 50 mg/kg intraperitoneally. The PCX+ CVN group received 5 mg/kg PCX followed by 5 mg/kg CVN once a week. All animals were subjected to deterioration product otoacoustic emission testing before (day 0) and after drug administration (day 23). Results: PCX showed an ototoxic effect by weakening otoacoustic emission values. PCX leads to significant otoacoustic emission value shifts ameliorated by CVN co-treatment (for 2000Hz p< .001, for 4000 levels p< .01, for 6000Hz p< .001, and for 8000 Hz p< .01 in PCX+CVN group). Furthermore, the PCX group had significantly greater malondialdehyde levels and significantly lower glutathione levels in the cochlear tissues, compared to the other groups. Co-administered CVN with PCX reversed these effects, making oxidative stress parameters close to those of the control group (for GSH levels p< .001, for MDA levels p< .01 in the PCX+CVN group). Conclusion: According to the findings, CVN appears to preserve cochlear function in rats against the disruptive effects of PCX.